Eli Lilly and Company (NYSE:LLY) Shares Bought by Cassady Schiller Wealth Management LLC

Cassady Schiller Wealth Management LLC raised its position in Eli Lilly and Company (NYSE:LLYFree Report) by 23.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 434 shares of the company’s stock after purchasing an additional 83 shares during the period. Cassady Schiller Wealth Management LLC’s holdings in Eli Lilly and Company were worth $253,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LLY. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $26,000. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $29,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at $36,000. St. Johns Investment Management Company LLC boosted its stake in Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after buying an additional 37 shares during the last quarter. Finally, O Brien Wealth Partners LLC boosted its stake in Eli Lilly and Company by 70.5% in the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after buying an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on LLY shares. Truist Financial raised their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Barclays raised their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Argus raised their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Finally, BMO Capital Markets raised their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $769.53.

View Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Stock Up 0.4 %

LLY stock traded up $3.03 during midday trading on Thursday, hitting $805.94. 2,043,969 shares of the company’s stock were exchanged, compared to its average volume of 2,995,820. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $820.61. The firm has a 50 day moving average price of $763.51 and a 200-day moving average price of $690.03. The stock has a market capitalization of $765.97 billion, a price-to-earnings ratio of 119.61, a price-to-earnings-growth ratio of 1.75 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the business earned $1.62 EPS. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 13.78 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.65%. Eli Lilly and Company’s payout ratio is 76.58%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.